Mylan Inc. and its subsidiary Mylan Pharmaceuticals are being sued by Bayer Healthcare, Bayer Healthcare Pharmaceuticals and Onyx Pharamceuticals in relation to the filing of an abbreviated new drug application for sorafenib tablets, the generic version of Nexavar.
A new, potentially far-reaching program to encourage individuals to take better charge of their own health is taking shape in the United Kingdom. And given the increasingly globalized marketplace, the emergence of Walgreens Boots Alliance as an international pharmacy powerhouse and the ongoing struggle by U.S. pharmacies to gain provider status and reimbursement for a growing menu of patient-care services, that campaign could spark or help inform similar efforts on this side of the Atlantic.
Generic drug prices are going up. Spurred by market opportunities, short-term market exclusivity for some newly launched single-source generics and rising costs for manufacturing, quality control and raw materials, me-too drug manufacturers have escalated a series of price hikes, some of them significant.